Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 568 entries
Sorted by: Best Match Show Resources per page
Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis.

Oncotarget

Yang L, Guo G, Sun L, Li C, Zhang H.
PMID: 28938689
Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29.

BACKGROUND: Ovarian neoplasm is a kind of high risky cancer among female. This paper assessed the efficacy and safety of twelve therapies and figured out the superior chemotherapeutic drug for ovarian cancer through network meta-analysis (NMA).METHOD: Eligible randomized controlled...

Cite
Yang L, Guo G, Sun L, et al. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017;8(35):59867-59877doi: 10.18632/oncotarget.16729.
Yang, L., Guo, G., Sun, L., Li, C., & Zhang, H. (2017). Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget, 8(35), 59867-59877. https://doi.org/10.18632/oncotarget.16729
Yang, Lili, et al. "Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis." Oncotarget vol. 8,35 (2017): 59867-59877. doi: https://doi.org/10.18632/oncotarget.16729
Yang L, Guo G, Sun L, Li C, Zhang H. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. Oncotarget. 2017 Mar 30;8(35):59867-59877. doi: 10.18632/oncotarget.16729. eCollection 2017 Aug 29. PMID: 28938689; PMCID: PMC5601785.
Copy Download .nbib Format: NLM
Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.

Molecular and clinical oncology

Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y.
PMID: 26137283
Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03.

The aim of the present study was to predict the effects of transarterial infusion (TAI) chemotherapy based on early changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in patients with advanced hepatocellular carcinoma (HCC). Seventy-four patients who underwent TAI...

Cite
Oyama K, Koda M, Sugihara T, et al. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015;3(3):655-662doi: 10.3892/mco.2015.523.
Oyama, K., Koda, M., Sugihara, T., Kishina, M., Miyoshi, K., Okamoto, T., Hodotsuka, M., Fujise, Y., Matono, T., Tokunaga, S., Okamoto, K., Hosho, K., Okano, J., & Murawaki, Y. (2015). Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Molecular and clinical oncology, 3(3), 655-662. https://doi.org/10.3892/mco.2015.523
Oyama, Kenji, et al. "Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma." Molecular and clinical oncology vol. 3,3 (2015): 655-662. doi: https://doi.org/10.3892/mco.2015.523
Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03. PMID: 26137283; PMCID: PMC4471610.
Copy Download .nbib Format: NLM
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Oncology letters

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.
PMID: 28356963
Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

In patients with advanced urothelial cancer (UC), a combination of cisplatin (CDDP) and gemcitabine (GEM) is the most commonly used first-line systematic chemotherapy regimen. Although no standard regime for the treatment of CDDP-resistant UC has been established, GEM-based regimens...

Cite
Miyata Y, Mitsunari K, Akihiro A, et al. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2016;13(2):811-818doi: 10.3892/ol.2016.5484.
Miyata, Y., Mitsunari, K., Akihiro, A., Watanabe, S. I., Matsuo, T., Ohba, K., & Sakai, H. (2017). Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncology letters, 13(2), 811-818. https://doi.org/10.3892/ol.2016.5484
Miyata, Yasuyoshi, et al. "Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer." Oncology letters vol. 13,2 (2017): 811-818. doi: https://doi.org/10.3892/ol.2016.5484
Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H. Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12. PMID: 28356963; PMCID: PMC5351343.
Copy Download .nbib Format: NLM
Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma.

World journal of clinical oncology

Cecchini S, Sarti D, Ricci S, Vergini LD, Sallei M, Serresi S, Ricotti G, Mulazzani L, Lattanzio F, Fiorentini G.
PMID: 26266102
World J Clin Oncol. 2015 Aug 10;6(4):57-63. doi: 10.5306/wjco.v6.i4.57.

AIM: To better define the efficacy and the safety of intra-arterial infusion performed with or without hemofiltration for recurrent limb melanoma.METHODS: Patients with the following characteristics were included in the study: recurrent limb melanoma not indicated for surgical resection,...

Cite
Cecchini S, Sarti D, Ricci S, et al. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World J Clin Oncol. 2015;6(4):57-63doi: 10.5306/wjco.v6.i4.57.
Cecchini, S., Sarti, D., Ricci, S., Vergini, L. D., Sallei, M., Serresi, S., Ricotti, G., Mulazzani, L., Lattanzio, F., & Fiorentini, G. (2015). Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World journal of clinical oncology, 6(4), 57-63. https://doi.org/10.5306/wjco.v6.i4.57
Cecchini, Sara, et al. "Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma." World journal of clinical oncology vol. 6,4 (2015): 57-63. doi: https://doi.org/10.5306/wjco.v6.i4.57
Cecchini S, Sarti D, Ricci S, Vergini LD, Sallei M, Serresi S, Ricotti G, Mulazzani L, Lattanzio F, Fiorentini G. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World J Clin Oncol. 2015 Aug 10;6(4):57-63. doi: 10.5306/wjco.v6.i4.57. PMID: 26266102; PMCID: PMC4530379.
Copy Download .nbib Format: NLM
Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.

Sarcoma

Hirbe AC, Cosper PF, Dahiya S, Van Tine BA.
PMID: 28546782
Sarcoma. 2017;2017:3761292. doi: 10.1155/2017/3761292. Epub 2017 May 04.

No abstract available.

Cite
Hirbe AC, Cosper PF, Dahiya S, et al. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017;2017:3761292doi: 10.1155/2017/3761292.
Hirbe, A. C., Cosper, P. F., Dahiya, S., & Van Tine, B. A. (2017). Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma, 20173761292. https://doi.org/10.1155/2017/3761292
Hirbe, Angela C, et al. "Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors." Sarcoma vol. 2017 (2017): 3761292. doi: https://doi.org/10.1155/2017/3761292
Hirbe AC, Cosper PF, Dahiya S, Van Tine BA. Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017;2017:3761292. doi: 10.1155/2017/3761292. Epub 2017 May 04. PMID: 28546782; PMCID: PMC5435903.
Copy Download .nbib Format: NLM
Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning.

F1000Research

Mucaki EJ, Baranova K, Pham HQ, Rezaeian I, Angelov D, Ngom A, Rueda L, Rogan PK.
PMID: 28620450
F1000Res. 2016 Aug 31;5:2124. doi: 10.12688/f1000research.9417.3. eCollection 2016.

Genomic aberrations and gene expression-defined subtypes in the large METABRIC patient cohort have been used to stratify and predict survival. The present study used normalized gene expression signatures of paclitaxel drug response to predict outcome for different survival times...

Cite
Mucaki EJ, Baranova K, Pham HQ, et al. Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. F1000Res. 2016;5:2124doi: 10.12688/f1000research.9417.3.
Mucaki, E. J., Baranova, K., Pham, H. Q., Rezaeian, I., Angelov, D., Ngom, A., Rueda, L., & Rogan, P. K. (2016). Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. F1000Research, 52124. https://doi.org/10.12688/f1000research.9417.3
Mucaki, Eliseos J, et al. "Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning." F1000Research vol. 5 (2016): 2124. doi: https://doi.org/10.12688/f1000research.9417.3
Mucaki EJ, Baranova K, Pham HQ, Rezaeian I, Angelov D, Ngom A, Rueda L, Rogan PK. Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. F1000Res. 2016 Aug 31;5:2124. doi: 10.12688/f1000research.9417.3. eCollection 2016. PMID: 28620450; PMCID: PMC5461908.
Copy Download .nbib Format: NLM
Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature.

Oncology letters

Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H.
PMID: 27123064
Oncol Lett. 2016 May;11(5):3064-3070. doi: 10.3892/ol.2016.4334. Epub 2016 Mar 16.

While tumor size, the presence of inflammatory carcinoma and lymph node involvement are the main prognostic factors of women with locally advanced breast cancer, the prognostic value of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor...

Cite
Kiba T, Morii N, Takahashi H, et al. Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature. Oncol Lett. 2016;11(5):3064-3070doi: 10.3892/ol.2016.4334.
Kiba, T., Morii, N., Takahashi, H., Ozaki, S., Atsumi, M., Masumoto, F., & Yamashiro, H. (2016). Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature. Oncology letters, 11(5), 3064-3070. https://doi.org/10.3892/ol.2016.4334
Kiba, Takayoshi, et al. "Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature." Oncology letters vol. 11,5 (2016): 3064-3070. doi: https://doi.org/10.3892/ol.2016.4334
Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H. Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature. Oncol Lett. 2016 May;11(5):3064-3070. doi: 10.3892/ol.2016.4334. Epub 2016 Mar 16. PMID: 27123064; PMCID: PMC4841046.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer.

Radiology and oncology

He J, Wang X, Guan H, Chen W, Wang M, Wu H, Wang Z, Zhou R, Qiu S.
PMID: 22933945
Radiol Oncol. 2011 Jun;45(2):123-8. doi: 10.2478/v10019-011-0014-7. Epub 2011 Apr 23.

BACKGROUND: The aim of the study was to evaluate the clinical efficacy of superselective intra-arterial targeted neo-adjuvant chemotherapy in the treatment of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) breast cancer....

Cite
He J, Wang X, Guan H, et al. Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiol Oncol. 2011;45(2):123-8doi: 10.2478/v10019-011-0014-7.
He, J., Wang, X., Guan, H., Chen, W., Wang, M., Wu, H., Wang, Z., Zhou, R., & Qiu, S. (2011). Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiology and oncology, 45(2), 123-8. https://doi.org/10.2478/v10019-011-0014-7
He, Jinsong, et al. "Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer." Radiology and oncology vol. 45,2 (2011): 123-8. doi: https://doi.org/10.2478/v10019-011-0014-7
He J, Wang X, Guan H, Chen W, Wang M, Wu H, Wang Z, Zhou R, Qiu S. Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer. Radiol Oncol. 2011 Jun;45(2):123-8. doi: 10.2478/v10019-011-0014-7. Epub 2011 Apr 23. PMID: 22933945; PMCID: PMC3423732.
Copy Download .nbib Format: NLM
A case of metaplastic breast cancer in a man.

Journal of surgical case reports

Barr JG, Jane Clayton ES, Sotheran W.
PMID: 24964410
J Surg Case Rep. 2013 Feb 07;2013(2). doi: 10.1093/jscr/rjs047.

Metaplastic breast cancers (MPBCs) represent

Cite
Barr JG, Jane Clayton ES, Sotheran W. A case of metaplastic breast cancer in a man. J Surg Case Rep. 2013;2013(2)doi: 10.1093/jscr/rjs047.
Barr, J. G., Jane Clayton, E. S., & Sotheran, W. (2013). A case of metaplastic breast cancer in a man. Journal of surgical case reports, 2013(2), . https://doi.org/10.1093/jscr/rjs047
Barr, James Geoffrey, et al. "A case of metaplastic breast cancer in a man." Journal of surgical case reports vol. 2013,2 (2013). doi: https://doi.org/10.1093/jscr/rjs047
Barr JG, Jane Clayton ES, Sotheran W. A case of metaplastic breast cancer in a man. J Surg Case Rep. 2013 Feb 07;2013(2). doi: 10.1093/jscr/rjs047. PMID: 24964410; PMCID: PMC3789653.
Copy Download .nbib Format: NLM
A rare presentation of primary leiomyosarcoma of ovary in a young woman.

Ecancermedicalscience

Vijaya Kumar J, Khurana A, Kaur P, Chuahan AK, Singh S.
PMID: 25932048
Ecancermedicalscience. 2015 Apr 21;9:524. doi: 10.3332/ecancer.2015.524. eCollection 2015.

Primary ovarian leiomyosarcoma is a very rare tumour which is most commonly seen in postmenopausal women. A case is described here involving a 30-year-old female who presented with pain in the abdomen. The patient underwent laparotomy with peritoneal lavage,...

Cite
Vijaya Kumar J, Khurana A, Kaur P, et al. A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience. 2015;9:524doi: 10.3332/ecancer.2015.524.
Vijaya Kumar, J., Khurana, A., Kaur, P., Chuahan, A. K., & Singh, S. (2015). A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience, 9524. https://doi.org/10.3332/ecancer.2015.524
Vijaya Kumar, J, et al. "A rare presentation of primary leiomyosarcoma of ovary in a young woman." Ecancermedicalscience vol. 9 (2015): 524. doi: https://doi.org/10.3332/ecancer.2015.524
Vijaya Kumar J, Khurana A, Kaur P, Chuahan AK, Singh S. A rare presentation of primary leiomyosarcoma of ovary in a young woman. Ecancermedicalscience. 2015 Apr 21;9:524. doi: 10.3332/ecancer.2015.524. eCollection 2015. PMID: 25932048; PMCID: PMC4406529.
Copy Download .nbib Format: NLM
Association of survivin splice variants with prognosis and treatment of breast cancer.

World journal of clinical oncology

Pavlidou A, Kroupis C, Dimas K.
PMID: 25493226
World J Clin Oncol. 2014 Dec 10;5(5):883-94. doi: 10.5306/wjco.v5.i5.883.

The purpose of this study was the overview of current knowledge regarding the use of survivin and its isoforms in prognosis and treatment of breast cancer. An advanced search of Medline was performed using the following search strategy: "(survivin...

Cite
Pavlidou A, Kroupis C, Dimas K. Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol. 2014;5(5):883-94doi: 10.5306/wjco.v5.i5.883.
Pavlidou, A., Kroupis, C., & Dimas, K. (2014). Association of survivin splice variants with prognosis and treatment of breast cancer. World journal of clinical oncology, 5(5), 883-94. https://doi.org/10.5306/wjco.v5.i5.883
Pavlidou, Anastasia, et al. "Association of survivin splice variants with prognosis and treatment of breast cancer." World journal of clinical oncology vol. 5,5 (2014): 883-94. doi: https://doi.org/10.5306/wjco.v5.i5.883
Pavlidou A, Kroupis C, Dimas K. Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol. 2014 Dec 10;5(5):883-94. doi: 10.5306/wjco.v5.i5.883. PMID: 25493226; PMCID: PMC4259950.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 568 entries